PHAT Phathom Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-08 12:27
Why PHAT matters now
Phathom Pharmaceuticals, Inc. (PHAT) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.98 with +3.72% on the session and $955.5M in market capitalization; recent performance reads 1-month -4.56% and YTD -34.42%.
The latest financial table shown here is Q1 2026, with revenue of $58.3M, net income of $-30.4M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.2%.
The latest indexable market news headline is "Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.00; recent insider activity includes Parikh Asit filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.65
P/S
4.24
EV/EBITDA
-9.39
DCF Value
$-11.64
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.9%
Operating Margin
-47.1%
Net Margin
-76.8%
ROE
39.2%
ROA
-51.6%
ROIC
-53.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $58.3M | $-30.4M | $-0.37 |
| Q4 2025 | $57.6M | $-21.1M | $-0.29 |
| FY 2025 | $175.1M | $-221.2M | $-3.03 |
| Q3 2025 | $49.5M | $-30.0M | $-0.41 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$18.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.51
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.